At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1 enrolled
Drug / intervention
risperidonedrug
Likely dose
risperidone 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Actigraphic Analysis of Treatment Response in a Six Year Old Girl With Kabuki Syndrome
In Brief
A clinical study evaluating risperidone for Sleep Disorders, Circadian Rhythm and 2 related conditions. Completed, enrolled 1 participant across 1 site.
Detailed Summary
The study examines and illustrates the utility of utilizing actigraphic measurements to assess treatment response.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedJul 2008
Primary CompletionJul 2010
Study CompletionAug 2010
TodayJul 2026
First PostedJul 28, 2008
Enrollment StartMay 1, 2008
Primary CompletionJul 1, 2010
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 17.9 years ago
Interventions
risperidonedrug
Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).